BD Reports 12-Percent Rise in Fiscal Q3 Sales; R&D, Profit Post Gains | GenomeWeb
NEW YORK (GenomeWeb News) — Becton Dickinson today said that fiscal third-quarter revenues rose 11.6 percent as R&D spending climbed 21 percent and profit grew 19 percent.
 
Total receipts for the three months ended June 30 increased to $1.63 billion from $1.46 billion year over year.
 
BD said revenues from its Diagnostics segment grew 15 percent to $492 million, while Biosciences revenue rose 13 percent to $258 million. Revenue from the Medical segment rose 10 percent to $882 million.  
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.